Withdrawal strategies could be suitable for certain patients, keeping in mind that several factors influence withdrawal decisions, including treatment response, disease activity and monitoring, and patient characteristics. The decision to withdraw TNFi must balance the benefits against the potential risks of disease flare and long-term treatment-related adverse effects. Combining DMARDs and TNFi early improves outcomes, supporting tapering strategies for cost-effectiveness and flare prevention. Future directions, including precision medicine approaches, patient-centered care models, and health economics analyses, are proposed to further optimize RA management and improve patient outcomes.
Keyphrases
- rheumatoid arthritis
- disease activity
- rheumatoid arthritis patients
- systemic lupus erythematosus
- ankylosing spondylitis
- healthcare
- end stage renal disease
- chronic kidney disease
- interstitial lung disease
- public health
- juvenile idiopathic arthritis
- newly diagnosed
- ejection fraction
- palliative care
- peritoneal dialysis
- mental health
- case report
- type diabetes
- risk assessment
- weight loss
- health information
- decision making
- systemic sclerosis
- metabolic syndrome